Intangible assets

12 Months Ended

Dec. 31, 2011

Intangible assets [Abstract]

Intangible assets

12. Intangible assets

Finite-lived and indefinite-lived identifiable intangible assets consisted of the following as of December 31, 2011 and 2010 (in millions):

	2011						2010
	Gross carrying amount		Accumulated amortization		Intangible assets, net		Gross carrying amount		Accumulated amortization		Intangible assets, net
Finite-lived intangible assets:
Acquired product technology rights:
Developed product technology	$	2,872	$	(1,811)	$	1,061	$	2,872	$	(1,619)	$	1,253
Core technology		1,348		(850)		498		1,348		(760)		588
Trade name		190		(120)		70		190		(107)		83
Acquired R&D technology rights		350		(350)		—		350		(329)		21
Other acquired intangible assets		686		(406)		280		627		(342)		285
Total finite-lived intangible assets		5,446		(3,537)		1,909		5,387		(3,157)		2,230
Indefinite-lived intangible assets — IPR&D		675		—		675		—		—		—
Total identifiable intangible assets	$	6,121	$	(3,537)	$	2,584	$	5,387	$	(3,157)	$	2,230

Amortization of finite-lived intangible assets is provided over their estimated useful lives ranging from 5 to 15 years on a straight-line basis.

Acquired product technology rights relate to the identifiable intangible assets acquired in connection with the 2002 Immunex acquisition and the related amortization expense is included in Amortization of certain acquired intangible assets in the Consolidated Statements of Income. Acquired R&D technology rights consist of technology used in R&D with alternative future uses and the related amortization expense is included in Research and development expense in the Consolidated Statements of Income. The amortization expense related to other acquired intangible assets is included principally in Cost of sales (excludes amortization of certain acquired intangible assets) and Selling, general and administrative expense in the Consolidated Statements of Income. During the years ended December 31, 2011, 2010 and 2009, we recognized amortization charges associated with our finite-lived intangible assets of $380 million, $423 million and $425 million, respectively. The total estimated amortization for each of the next five years for our intangible assets is $354 million, $359 million, $340 million, $327 million and $317 million in 2012, 2013, 2014, 2015 and 2016, respectively.

IPR&D relates to identifiable intangible assets acquired in connection with the acquisition of BioVex. (See Note 2, Business combinations — BioVex Group, Inc.)